Definitive Contract HT942525CE026
- Not listed
- The Defense Health Agency awarded a $1,999,090.13 Small Business Innovation Research (SBIR) Phase II contract to Ifyber LLC, a for-profit limited liability company, for the development of a rapid field testing capability for total coliform and E. coli in water samples. The contract, which is a firm fixed-price definitive contract, is intended to support medical research and development and has a completion date of January 23, 2023. The contract was awarded on August 27, 2018 under the DHA 2017.1...
- The Department of the Army Medical Command awarded a Small Business Innovation Research (SBIR) Phase I contract to Ifyber LLC, a for-profit limited liability company, on August 15, 2017. The contract, valued at $149,837.08, is for the development of "Compressive Habiliment Integrated Technology for Continuous Health Assessment Tasks." This SBIR Phase I award is part of the agency's S10 major program and has a definitive, firm-fixed-price contract type. The work is to be performed in...
- The U.S. Air Force Research Laboratory (AFRL) awarded a $1,245,650.00 SBIR Phase II contract to Nanoguard Medical Solutions, LLC, a small disadvantaged business, for the development of a "SAVING LIVES IN COMBAT - A REVOLUTIONARY NANOFIBER WOUND CARE" product. The contract is a firm fixed-price purchase order with a period of performance through February 17, 2026. This SBIR Phase II action is part of the AFRL's efforts to support the development of innovative technologies for defense...
- This is a $2,994,281.25 Firm Fixed Price contract awarded by the Defense Health Agency (DHA) to Paranano Wound Care LLC, a small business, under the SBIR (Small Business Innovation Research) program. The contract is for Phase II of a project titled "The BIOZ Smart Bandage Empowering Priority Response to Pathogen Invasion in Wounds" and has an ultimate completion date of July 11, 2027. The contract is focused on medical research and development related to wound care and pathogen...
- The Department of Defense, specifically the Army Medical Command, awarded a $250,000 firm fixed price contract to Critical Innovations LLC of Inglewood, California. The contract is for Phase I of a Small Business Innovation Research proposal related to Department of Defense topic DHA213-009, which involves the development of a wearable wound infection treatment device. The period of performance is from March 25, 2022 through October 24, 2022. The contract has a total small business set aside...
- This is a Small Business Innovation Research (SBIR) Phase II contract awarded by the Medical Command (MEDCOM) of the Defense Health Agency (DHA) to Critical Innovations LLC, a small business LLC. The $1,100,000.00 contract is for the development of the "RX-Shooter Wearable Wound Infection Treatment Device" under Topic DHA213-009. The award is designated as a total small business set-aside. Critical Innovations is an ISO 13485:2016 certified medical research and development company that...
- The Department of the Army awarded a $167,499.96 firm-fixed-price Phase I Small Business Innovation Research (SBIR) program contract to Critical Innovations LLC, a limited liability company, for research and development efforts to develop treatments for dermal injuries caused by sulfur mustard. The contract has a total small business set-aside designation. Critical Innovations has previously received over $10 million in SBIR contracts from the Army, Defense Health Agency, and Air Force for...
- The Defense Health Agency has awarded a $249,962.26 Small Business Innovation Research (SBIR) Phase I contract to Applied Nanotech, Inc., doing business as Fepet, for the development of MicroBeID, a point-of-care, electronics-free molecular diagnostic platform for microbial detection. The contract, issued as a firm fixed-price purchase order with an ultimate completion date of March 21, 2026, is designated as a total small business set-aside and supports medical research and development...
- The Defense Health Agency awarded a $3.0 million Phase II Small Business Innovation Research (SBIR) contract to Technology Holding LLC, a small business based in Salt Lake City, Utah, for the development of a novel biologic countermeasure for acute radiation syndrome. This 23-month effort, which commenced on June 21, 2022, and concludes October 20, 2026, is structured as a firm fixed-price definitive contract under the SBIR program's Phase II action, which supports innovative research and...
- This is a SBIR (Small Business Innovation Research) Phase II contract awarded by the Defense Health Agency to Innosense Corporation, a small disadvantaged minority-owned business. The $999,998.59 contract is for research and development work related to the SBIR program. SBIR Phase II contracts provide funding for further development and prototyping of innovative technologies that were initially explored in a Phase I award. The contract is a cost-plus-fixed-fee type, which is common for this type...
The Defense Health Agency has awarded a $1.3 million Phase II Small Business Innovation Research (SBIR) contract to Ifyber LLC, a small business specializing in biofilm characterization and medical device testing. The definitive contract, with a firm fixed price arrangement, runs through January 2028 and is set aside for total small business participation. Work will be performed in Ithaca, New York, and builds on the company's existing research into antimicrobial and anti-biofilm technologies for military wound care applications. The SBIR Phase II program supports the continued development and commercialization of innovative technologies that address critical defense and health priorities. Ifyber LLC brings substantial relevant experience to this effort, having previously received a $3.2 million Defense Health Agency grant for standard-issue copper-based antimicrobial military wound dressing research and a $299,356 NIH grant for the development of nitric oxide-releasing wound care formulations. The company's core capabilities in chemistry, biology, regulatory affairs, and quality assurance position it well to advance antimicrobial combat wound care solutions that could benefit military personnel in field medical settings. This Phase II award represents continued federal investment in the company's innovative approaches to preventing infection and biofilm formation in combat-related burn and wound injuries.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.3m | 9/9/25 |